WBR0738: Difference between revisions

Jump to navigation Jump to search
Rim Halaby (talk | contribs)
Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Physiology |SubCategory=Endocrine, Renal |MainCategory=Physiology |SubCategory=Endocrine, Renal |Mai..."
 
WikiBot (talk | contribs)
m refreshing WBR questions
 
(6 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor= {{YD}} (Reviewed by  {{YD}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Physiology
|MainCategory=Physiology
Line 8: Line 8:
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Endocrine, Renal
|SubCategory=Endocrine, Renal
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
|MainCategory=Physiology
Line 20: Line 21:
|MainCategory=Physiology
|MainCategory=Physiology
|SubCategory=Endocrine, Renal
|SubCategory=Endocrine, Renal
|Prompt=A researcher is studying the effect of a new medication, MedX. He uses mice to conduct his experiments. Following the intravenous administration of MedX, the researcher notes the decreased secretion of aldosterone secondary to MedX's effect in reducing the production of a compound from the pulmonary vasculature. Based on the image below, which of the following reactions is most likely the first to be inhibited upon administration of MedX?
|Prompt=A researcher is studying the effect of a new medication, MedX. He uses mice to conduct his experiments. Following the intravenous administration of MedX, the researcher notes a decreased secretion of aldosterone secondary to MedX's effect in reducing the production of a compound from the pulmonary vasculature. Based on the image below, which of the following reactions is most likely the first to be inhibited upon administration of MedX?
 
[[Image:WBR RAAS pathway.png|700px]]
|Explanation=The [[renin-angiotensin aldosterone system]] ([[RAAS]]) is a major hormonal pathway that plays a significant role in the control of arterial blood pressure, tissue perfusion, and extracellular volume. The RAAS pathway begins by the expression and secretion of [[renin]], the rate-limiting enzyme of the RAAS pathway. Renin is mainly synthesized and stored in the juxtraglomerular (JG) apparatus, which lines the afferent arteriole of the renal [[glomerulus]] and is composed of JG cells and [[macula densa]].


[[Image:WBR RAAS pathway.png|500px]]
Renin cleaves the N-terminal portion of [[angiotensinogen]], a compound that is mainly expressed by the liver at a stable rate. Angiotensinogen cleavage results in the formation of [[angiotensin I]], a biologically inert decapeptide. Angiotensin I is hydrolyzed by angiotensin-converting enzyme ([[ACE]]) or kininase II, an enzyme on plasma membranes of endothelial cells, neuroepithelial cells, and renal proximal tubule cells. ACE acts by removing the C-terminal dipeptide to form angiotensin II, an octapeptide. Also, ACE has a role in metabolizing [[bradykinin]] and [[kallidin]], which are important vasodilator peptides. Unlike angiotensin I, angiotensin II is an active potent vasoconstrictor. Angiotensin II is the primary effector of numerous actions.
|Explanation=The effects of MedX are similar to angiotensin-converting enzyme (ACE) inhibitors. ACE is an enzyme that is produced by the pulmonary vasculature and is responsible for the conversion of angiotensin I to angiotensin II. The inhibition of the ACE leads to the inhibition of the entire renin-angiotensin pathway and the reduced production of aldosterone.  


Educational Objective: ACE is an enzyme produced by the pulmonary vasculature. It normally converts angiotensin I to angiotensin II.
The effects of MedX are similar to angiotensin-converting enzyme (ACE) inhibitors. ACE is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II. The inhibition of the ACE leads to the inhibition of the entire renin-angiotensin pathway and the deficient production of aldosterone.
|AnswerA=A
|AnswerA=A
|AnswerAExp=Angiotensinogen is formed by the liver. It is converted to angiotensin I by renin. Renin is formed by the juxtraglomerular cells of the kidney.  
|AnswerAExp=Angiotensinogen is formed by the liver. It is converted to angiotensin I by renin. Renin is synthesized and stored in the juxtraglomerular apparatus of the kidney.
|AnswerB=B
|AnswerB=B
|AnswerBExp=Angiotensin-converting enzyme (ACE) is found in the pulmonary vasculature. It normally converts angiotensin I to angiotensin II.
|AnswerBExp=Angiotensin-converting enzyme (ACE) is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II.
|AnswerC=C
|AnswerC=C
|AnswerCExp=ACE does not act at the level of the angiotensin receptor.
|AnswerCExp=ACE does not act at this level of the pathway.
|AnswerD=D
|AnswerD=D
|AnswerDExp=ACE does not act at the level of the angiotensin receptor.
|AnswerDExp=ACE does not act at this level of the pathway.
|AnswerE=E
|AnswerE=E
|AnswerEExp=ACE does not act at the level beyond the activation of the receptor.
|AnswerEExp=ACE does not act at this level of the pathway.
|EducationalObjectives=Angiotensin-converting enzyme (ACE) is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II.
|References=Atlas SA, The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8):S9-20.<br>
Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl. 1993;11(3):S49-S52.<br>
First Aid 2014 page 530
|RightAnswer=B
|RightAnswer=B
|WBRKeyword=angiotensin, converting, enzyme, ACE, inhibitor, angiotensinogen, renin, pulmonary, vasculature, vessel, vessels, hormone, conversion, convert, angiotensin I, angiotensin II, angiotensin 1, angiotensin 2, aldosterone
|WBRKeyword=Angiotensin, Converting, Enzyme, ACE, Inhibitor, ACE inhibitor, Angiotensinogen, Renin, Pulmonary, Vasculature, Hormone, Conversion, Angiotensin I, Angiotensin II, Angiotensin 1, Angiotensin 2, Aldosterone
|Approved=No
|Approved=Yes
}}
}}

Latest revision as of 01:32, 28 October 2020

 
Author [[PageAuthor::Yazan Daaboul, M.D. (Reviewed by Yazan Daaboul, M.D.)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Physiology
Sub Category SubCategory::Endocrine, SubCategory::Renal
Prompt [[Prompt::A researcher is studying the effect of a new medication, MedX. He uses mice to conduct his experiments. Following the intravenous administration of MedX, the researcher notes a decreased secretion of aldosterone secondary to MedX's effect in reducing the production of a compound from the pulmonary vasculature. Based on the image below, which of the following reactions is most likely the first to be inhibited upon administration of MedX?

]]

Answer A AnswerA::A
Answer A Explanation AnswerAExp::Angiotensinogen is formed by the liver. It is converted to angiotensin I by renin. Renin is synthesized and stored in the juxtraglomerular apparatus of the kidney.
Answer B AnswerB::B
Answer B Explanation AnswerBExp::Angiotensin-converting enzyme (ACE) is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II.
Answer C AnswerC::C
Answer C Explanation AnswerCExp::ACE does not act at this level of the pathway.
Answer D AnswerD::D
Answer D Explanation AnswerDExp::ACE does not act at this level of the pathway.
Answer E AnswerE::E
Answer E Explanation AnswerEExp::ACE does not act at this level of the pathway.
Right Answer RightAnswer::B
Explanation [[Explanation::The renin-angiotensin aldosterone system (RAAS) is a major hormonal pathway that plays a significant role in the control of arterial blood pressure, tissue perfusion, and extracellular volume. The RAAS pathway begins by the expression and secretion of renin, the rate-limiting enzyme of the RAAS pathway. Renin is mainly synthesized and stored in the juxtraglomerular (JG) apparatus, which lines the afferent arteriole of the renal glomerulus and is composed of JG cells and macula densa.

Renin cleaves the N-terminal portion of angiotensinogen, a compound that is mainly expressed by the liver at a stable rate. Angiotensinogen cleavage results in the formation of angiotensin I, a biologically inert decapeptide. Angiotensin I is hydrolyzed by angiotensin-converting enzyme (ACE) or kininase II, an enzyme on plasma membranes of endothelial cells, neuroepithelial cells, and renal proximal tubule cells. ACE acts by removing the C-terminal dipeptide to form angiotensin II, an octapeptide. Also, ACE has a role in metabolizing bradykinin and kallidin, which are important vasodilator peptides. Unlike angiotensin I, angiotensin II is an active potent vasoconstrictor. Angiotensin II is the primary effector of numerous actions.

The effects of MedX are similar to angiotensin-converting enzyme (ACE) inhibitors. ACE is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II. The inhibition of the ACE leads to the inhibition of the entire renin-angiotensin pathway and the deficient production of aldosterone.
Educational Objective: Angiotensin-converting enzyme (ACE) is synthesized in various cells, including the endothelial cells of the pulmonary vasculature. ACE converts angiotensin I to angiotensin II.
References: Atlas SA, The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8):S9-20.
Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl. 1993;11(3):S49-S52.
First Aid 2014 page 530]]

Approved Approved::Yes
Keyword WBRKeyword::Angiotensin, WBRKeyword::Converting, WBRKeyword::Enzyme, WBRKeyword::ACE, WBRKeyword::Inhibitor, WBRKeyword::ACE inhibitor, WBRKeyword::Angiotensinogen, WBRKeyword::Renin, WBRKeyword::Pulmonary, WBRKeyword::Vasculature, WBRKeyword::Hormone, WBRKeyword::Conversion, WBRKeyword::Angiotensin I, WBRKeyword::Angiotensin II, WBRKeyword::Angiotensin 1, WBRKeyword::Angiotensin 2, WBRKeyword::Aldosterone
Linked Question Linked::
Order in Linked Questions LinkedOrder::